Early Detection Research Network

Pancreas

No data available.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/25/918
Under Review
One
No data available.
709940ce142847918e612ada36e7583f
no
no
Contents
Pancreatic Reference Set Application: Brian Haab-Van Andel (2012)

New markers are greatly needed for the detection and diagnosis of pancreatic cancer. Patients at high risk for developing pancreatic cancer (for, example because of genetic predisposition or health status) can be screened by endoscopy or a related imaging procedure, but these methods are expensive and burdensome to the patient. Blood-based markers would facilitate regular screening. In addition, patients with known abnormalities of the pancreas (for example, as observed incidentally from an abdominal scan) need to determine whether they have cancer or not. The great majority of patients with pancreatic findings by CT do not have conditions that require treatment, yet nearly all patients undergo invasive and burdensome procedures as a consequence of the CT. Again, a blood-based marker could alleviate this situation and potentially add accuracy to the diagnosis. In preliminary work we showed the potential for highly-accurate discrimination of pancreatic cancer from pancreatitis and healthy control subjects using a panel of protein and glycan markers in the serum. We used an antibody array platform in which we can obtain sensitive, reproducible measurements of protein abundance and glycosylation status in low sample volumes. The detection of the glycosylation status is important for the high accuracy of the test because the glycans attached to the marker proteins are altered in cancer patients. Based on the good performance in these early studies, we now want to validate the performance in rigorously controlled, blinded sample sets. The reference set developed by the EDRN will enable a definitive characterization of our marker performance. In addition, we can make an accurate comparison to other markers that will be applied to the same set and determine whether disparate markers could be used together for added benefit.